On Monday, ASX-listed Irish healthcare company Oneview Healthcare Limited (ASX: ONE) announced a pilot project to measure the impact of a new electronic patient care pathway for prostate cancer patients. The collaborative project, with partners including the University of Oxford, is expected to commence in March 2017. The company said the project may lead to commercialisation opportunities. We believe Oneview will continue to gain market share both domestically and globally through capitalising on their innovative and superior product suite. Shares in Oneview closed flat for the week. We own Oneview as a research-driven investment in WAM Capital and WAM Research.
Please sign in to comment on this wire.